


RealRate

PHARMACEUTICAL 2018

Apellis Pharmaceuticals Inc. Rank 74 of 342





Apellis





Apellis Pharmaceuticals Inc. Rank 74 of 342



The relative strengths and weaknesses of Apellis Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Apellis Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 130% points. The greatest weakness of Apellis Pharmaceuticals Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 191%, being 145% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	182,015
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,554
Liabilities, Non-Current	0
Other Assets	116
Other Compr. Net Income	0
Other Expenses	154
Other Liabilities	26,635
Other Net Income	-50,864
Other Revenues	12
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	182,131
Liabilities	33,189
Expenses	154
Revenues	12
Stockholders Equity	148,943
Net Income	-51,006
Comprehensive Net Income	-51,006
Economic Capital Ratio	191%

